ThromboGenics Takes Its Time On Solo Launch Of Eye Drug Jetrea

Having taken a conservative approach to its first commercial launch, ThromboGenics plans to roll out newly approved eye drug Jetrea (ocriplasmin) in January 2013. Company is now recruiting a sales force to target retinal specialists, who are already well aware of the new drug.